EP300 and prostate cancer: The I-CBP112, a ligand for p300/CBP bromodomains, stimulates the acetylation of H3K18 in acute leukemia and prostate cancer cells and exerts antiproliferative effects that reveal a novel strategy for treating cancer by modulating histone acetylation [150].